ES2621664T3 - Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico - Google Patents

Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Download PDF

Info

Publication number
ES2621664T3
ES2621664T3 ES12846895.6T ES12846895T ES2621664T3 ES 2621664 T3 ES2621664 T3 ES 2621664T3 ES 12846895 T ES12846895 T ES 12846895T ES 2621664 T3 ES2621664 T3 ES 2621664T3
Authority
ES
Spain
Prior art keywords
dihydroquinolin
cyclopropylamino
fluoroethyl
fluoro
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846895.6T
Other languages
English (en)
Spanish (es)
Inventor
Ichiro Araya
Akinori Goto
Wataru Minagawa
Keiko Funada
Muneki Nagao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48289529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2621664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2621664T3 publication Critical patent/ES2621664T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES12846895.6T 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico Active ES2621664T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011246209 2011-11-10
JP2011246209 2011-11-10
JP2012071739 2012-03-27
JP2012071739 2012-03-27
PCT/JP2012/007195 WO2013069297A1 (ja) 2011-11-10 2012-11-09 ７－｛（３s、４s）－３－［（シクロプロピルアミノ)メチル］－４－フルオロピロリジン－1－イル｝－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１、４－ジヒドロキノリン－３－カルボン酸の結晶

Publications (1)

Publication Number Publication Date
ES2621664T3 true ES2621664T3 (es) 2017-07-04

Family

ID=48289529

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12846895.6T Active ES2621664T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16177827T Active ES2747303T3 (es) 2011-11-10 2012-11-09 Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico

Country Status (17)

Country Link
US (3) US9090587B2 (enExample)
EP (2) EP3112359B1 (enExample)
JP (4) JP5871948B2 (enExample)
KR (2) KR20140098074A (enExample)
CN (2) CN104945375B (enExample)
AU (1) AU2016273899B2 (enExample)
BR (1) BR112014010765B1 (enExample)
CA (1) CA2855022C (enExample)
ES (2) ES2621664T3 (enExample)
IN (1) IN2014DN03277A (enExample)
MX (1) MX375073B (enExample)
NZ (1) NZ623808A (enExample)
RU (2) RU2017109814A (enExample)
SA (1) SA112330992B1 (enExample)
SG (2) SG10201608167UA (enExample)
TW (1) TWI547492B (enExample)
WO (1) WO2013069297A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
CA2910121A1 (en) * 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent
WO2014174848A1 (ja) * 2013-04-25 2014-10-30 杏林製薬株式会社 錠剤
CA2910112C (en) * 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US10154993B2 (en) * 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
WO2016063544A1 (ja) * 2014-10-23 2016-04-28 杏林製薬株式会社 固形医薬組成物
MY191848A (en) * 2015-03-13 2022-07-18 Kyorin Seiyaku Kk Respiratory infection treating agent
US10206917B2 (en) * 2015-06-02 2019-02-19 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
EP3305294A4 (en) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
AU2018283234A1 (en) 2017-06-16 2019-12-12 Kyorin Pharmaceutical Co., Ltd. Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess
KR20240096794A (ko) * 2017-06-16 2024-06-26 교린 세이야꾸 가부시키 가이샤 흡인성 폐렴, 폐화농증 또는 폐농양의 치료제
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA944369B (en) * 1993-08-27 1995-02-13 Hokuriku Seuyaku Co Ltd 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
CN1158846A (zh) 1995-05-09 1997-09-10 昆山市康壮达兽药厂 盐酸氟哌酸的合成工艺
EP1425577A4 (en) 2001-08-10 2004-12-29 Symyx Technologies Inc APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
WO2003076428A1 (en) * 2002-03-08 2003-09-18 Daiichi Pharmaceutical Co., Ltd. Quinolonecarboxylic acid derivative
CN100410249C (zh) 2003-09-10 2008-08-13 杏林制药株式会社 7-(4-取代-3-环丙基氨基甲基-1-吡咯烷基)喹诺酮羧酸衍生物
CN101003540A (zh) * 2006-01-18 2007-07-25 广州白云山制药股份有限公司广州白云山制药总厂 一种抗感染化合物和用途
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي

Also Published As

Publication number Publication date
NZ623808A (en) 2015-07-31
JPWO2013069297A1 (ja) 2015-04-02
US20140288310A1 (en) 2014-09-25
AU2016273899A1 (en) 2017-01-12
IN2014DN03277A (enExample) 2015-05-22
CN104945375B (zh) 2017-07-04
RU2615509C2 (ru) 2017-04-05
MX375073B (es) 2025-03-06
CN103930414A (zh) 2014-07-16
KR102162208B1 (ko) 2020-10-06
KR20190065456A (ko) 2019-06-11
RU2014123567A (ru) 2015-12-20
RU2017109814A (ru) 2019-01-23
SG11201401817TA (en) 2014-08-28
AU2012337206B2 (en) 2016-09-15
USRE47785E1 (en) 2019-12-31
SA112330992B1 (ar) 2015-09-13
JP6514069B2 (ja) 2019-05-15
JP2017160243A (ja) 2017-09-14
BR112014010765B1 (pt) 2020-07-14
TW201332991A (zh) 2013-08-16
WO2013069297A1 (ja) 2013-05-16
ES2747303T3 (es) 2020-03-10
JP2018158949A (ja) 2018-10-11
JP5871948B2 (ja) 2016-03-01
EP3112359B1 (en) 2019-08-21
EP2778159A4 (en) 2015-06-03
US9328089B2 (en) 2016-05-03
JP6818719B2 (ja) 2021-01-20
US20150284361A1 (en) 2015-10-08
BR112014010765A2 (pt) 2017-06-13
SG10201608167UA (en) 2016-11-29
RU2017109814A3 (enExample) 2020-04-08
TWI547492B (zh) 2016-09-01
CA2855022C (en) 2019-05-07
CN103930414B (zh) 2016-01-20
US9090587B2 (en) 2015-07-28
JP6349435B2 (ja) 2018-06-27
KR20140098074A (ko) 2014-08-07
AU2012337206A8 (en) 2016-09-22
EP2778159A1 (en) 2014-09-17
AU2012337206A1 (en) 2014-05-22
EP2778159B1 (en) 2017-03-01
EP3112359A1 (en) 2017-01-04
AU2016273899B2 (en) 2017-07-27
CN104945375A (zh) 2015-09-30
JP2016027045A (ja) 2016-02-18
CA2855022A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
ES2621664T3 (es) Cristal de ácido 7-{(3S,4S)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(2-fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico
ES2493940T3 (es) Una forma amorfa y una forma cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
ES2565521T3 (es) Polimorfos de dasatinib y proceso para la preparación de los mismos
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
HRP20241723T1 (hr) Kristalni toluen solvat od (s)-afoksolanera
ES2585221T3 (es) Un proceso para la preparación de 6-(7-((1-aminociclopropil)metoxi)-6-metoxiquinolin-4-iloxi)-n-metil-1-naftamida y productos intermedios sintéticos de la misma
ES2613716T3 (es) Formas cristalinas de un derivado de purina
NZ598277A (en) Process for preparing azabicyclic compounds
JP2010513494A5 (enExample)
HRP20180970T1 (hr) Policiklični lpa1 antagonist i njegove primjene
TW200463B (enExample)
UA119243C2 (uk) Сполуки індолізину, спосіб їх одержання і фармацевтичні композиції, що їх містять
CO6700138A1 (es) Procedimiento de preparación de sal de l-arginina de perindoprilo
RU2015117524A (ru) Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция
ES2543804T3 (es) Polimorfo B de Ibandronato
WO2015159236A1 (en) Polymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use
CN103709120A (zh) 一种盐酸阿考替胺三水合物的制备方法
EP4142707A1 (en) Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
CN103467466A (zh) 一种盐酸莫西沙星杂质的合成方法
AU2013385618A1 (en) Multifunctional quinoline derivatives as anti-neurodegenerative agents
SK50032014U1 (sk) Kryštalický dihydrát bilastínu
JP6230703B2 (ja) ４−ベンジル−１−フェネチル−ピペラジン−２，６−ジオンの製造方法、並びに、その中間体及び製造方法
AR085171A1 (es) Procedimiento para la produccion de sales de ralfinamida substancialmente libres de impurezas que tienen efectos genotoxicos, forma pseudopolimorfica de las mismas y formulacion farmaceutica que la contiene
MD4350B1 (ro) Forma cristalină delta a sării de L-arginină a perindoprilului, procedeu de obţinere a ei şi compoziţii farmaceutice care o conţin
RU2011143166A (ru) Новые кристаллические формы адефовира дипивоксила и способы его получения